These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38273969)

  • 1. Avapritinib treatment of aggressive systemic mastocytosis with a novel KIT exon 17 mutation.
    Sandow L; Town A; Heinrich MC
    Leuk Res Rep; 2024; 21():100409. PubMed ID: 38273969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approaches to treating advanced systemic mastocytosis.
    Gilreath JA; Tchertanov L; Deininger MW
    Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Avapritinib for the Treatment of Systemic Mastocytosis.
    Sumbly V; Landry I; Iqbal S; Bhatti Z; Alshamam MS; Ashfaq S; Rizzo V
    Cureus; 2021 Sep; 13(9):e18385. PubMed ID: 34729266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic mastocytosis mimicking blastic plasmacytoid dendritic cell neoplasm: a case report.
    Zhang X; Han J; Zhu N; Ji Y; Hou Y
    Diagn Pathol; 2023 Feb; 18(1):17. PubMed ID: 36759849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia.
    Sandow L; Heinrich M
    Leuk Res Rep; 2023; 19():100371. PubMed ID: 37305181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms.
    Tashi T; Deininger MW
    Immunol Allergy Clin North Am; 2023 Nov; 43(4):723-741. PubMed ID: 37758409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avapritinib for Systemic Mastocytosis.
    Bose P; Verstovsek S
    Expert Rev Hematol; 2021 Aug; 14(8):687-696. PubMed ID: 34289787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antineoplastic efficacy profiles of avapritinib and nintedanib in
    Degenfeld-Schonburg L; Gamperl S; Stefanzl G; Schruef AK; Sadovnik I; Bauer K; Smiljkovic D; Eisenwort G; Peter B; Greiner G; Hadzijusufovic E; Schwaab J; Sperr WR; Hoermann G; Kopanja S; Szépfalusi Z; Hoetzenecker K; Jaksch P; Reiter A; Arock M; Valent P
    Am J Cancer Res; 2023; 13(2):355-378. PubMed ID: 36895976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
    Shomali W; Gotlib J
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
    Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avapritinib for the treatment of KIT mutation-negative systemic mastocytosis.
    Azad F; Zhang J; Wang E
    Proc (Bayl Univ Med Cent); 2023; 36(1):81-82. PubMed ID: 36578586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.
    Reiter A; Schwaab J; DeAngelo DJ; Gotlib J; Deininger MW; Pettit KM; Alvarez-Twose I; Vannucchi AM; Panse J; Platzbecker U; Hermine O; Dybedal I; Lin HM; Rylova SN; Ehlert K; Dimitrijević S; Radia DH
    Blood Adv; 2022 Nov; 6(21):5750-5762. PubMed ID: 35640224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.
    Lübke J; Naumann N; Kluger S; Schwaab J; Metzgeroth G; Evans E; Gardino AK; Lengauer C; Hofmann WK; Fabarius A; Cross NCP; Reiter A; Jawhar M
    Leukemia; 2019 May; 33(5):1195-1205. PubMed ID: 30911112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap.
    Piris-Villaespesa M; Alvarez-Twose I
    Front Pharmacol; 2020; 11():443. PubMed ID: 32346366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
    Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
    Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
    Baird JH; Gotlib J
    Curr Hematol Malig Rep; 2018 Oct; 13(5):407-416. PubMed ID: 30155614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kit Mutations: New Insights and Diagnostic Value.
    Falchi L; Verstovsek S
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
    DeAngelo DJ; Radia DH; George TI; Robinson WA; Quiery AT; Drummond MW; Bose P; Hexner EO; Winton EF; Horny HP; Tugnait M; Schmidt-Kittler O; Evans EK; Lin HM; Mar BG; Verstovsek S; Deininger MW; Gotlib J
    Nat Med; 2021 Dec; 27(12):2183-2191. PubMed ID: 34873347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avapritinib for advanced systemic mastocytosis.
    Gotlib J; Reiter A; DeAngelo DJ
    Blood; 2022 Oct; 140(15):1667-1673. PubMed ID: 35877999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.
    Jara-Acevedo M; Teodosio C; Sanchez-Muñoz L; Álvarez-Twose I; Mayado A; Caldas C; Matito A; Morgado JM; Muñoz-González JI; Escribano L; Garcia-Montero AC; Orfao A
    Mod Pathol; 2015 Aug; 28(8):1138-49. PubMed ID: 26067933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.